(Q43248383)

17 November 2017

title

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis (English)

1 reference

17 November 2017

3

Ellen M Ginzler

1 reference

17 November 2017

Jai Radhakrishnan

1

1 reference

17 November 2017

Dimitrios-Anestis Moutzouris

2

1 reference

17 November 2017

Neil Solomons

4

1 reference

17 November 2017

Ilias I Siempos

5

1 reference

17 November 2017

Gerald B Appel

6

1 reference

17 November 2017

language of work or name

English

0 references

publication date

4 November 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

77

1 reference

17 November 2017

issue

2

1 reference

17 November 2017

page(s)

152-160

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2009.412

17 November 2017

exact match

0 references

cites work

An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Membranous lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Membranous lupus nephropathy: a clinicopathologic study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Lupus nephritis. Clinical course as related to morphologic forms and their transitions

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Mycophenolate therapy of SLE membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Update on the treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Lupus nephritis: treatment with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.412

7 January 2021

Identifiers

DOI

10.1038/KI.2009.412

1 reference

17 November 2017

1 reference